Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lydia Scarfò

Showing results (71-80 of 111) with videos related to

Pageof 12
Sort By:
The Lancet. Haematology|February 22, 2017
Lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplantation: an open label, single-arm, multicentre phase 2 trialAndrés J M Ferreri, Marianna Sassone, Francesco Zaja, et al.
Oncotarget|June 15, 2018
A novel <i>ex vivo</i> high-throughput assay reveals antiproliferative effects of idelalisib and ibrutinib in chronic lymphocytic leukemiaDaniel Primo, Lydia Scarfò, Aliki Xochelli, et al.
Cell Reports|February 16, 2016
Targeting Macrophages Sensitizes Chronic Lymphocytic Leukemia to Apoptosis and Inhibits Disease ProgressionGiovanni Galletti, Cristina Scielzo, Federica Barbaglio, et al.
Blood Advances|May 31, 2022
High surface IgM levels associate with shorter response to ibrutinib and BTK bypass in patients with CLLGiorgia Chiodin, Samantha Drennan, Enrica A Martino, et al.
The Lancet. Oncology|September 13, 2024
Atezolizumab, venetoclax, and obinutuzumab combination in Richter transformation diffuse large B-cell lymphoma (MOLTO): a multicentre, single-arm, phase 2 trialAlessandra Tedeschi, Anna Maria Frustaci, Adalgisa Condoluci, et al.
Hemasphere|March 18, 2025
Loss of CYLD promotes splenic marginal zone lymphomaAthanasios Pseftogas, Jessica Bordini, Silvia Heltai, et al.
Frontiers in Oncology|December 8, 2022
Obinutuzumab plus chlorambucil versus ibrutinib in previously untreated chronic lymphocytic leukemia patients without TP53 disruptions: A real-life CLL campus studyAndrea Visentin, Francesca Romana Mauro, Gioachino Catania, et al.
Leukemia & Lymphoma|March 8, 2022
Lenalidomide enhances CD23.CAR T cell therapy in chronic lymphocytic leukemiaSarah Tettamanti, Maria Caterina Rotiroti, Greta Maria Paola Giordano Attianese, et al.
ESMO Open|January 21, 2020
EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for haematological malignanciesBarbara Kiesewetter, Nathan I Cherny, Nicolas Boissel, et al.
Leukemia|April 4, 2024
IκBε deficiency accelerates disease development in chronic lymphocytic leukemiaJessica Bordini, Chiara Lenzi, Michela Frenquelli, et al.
Pageof 12

Showing results (71-80 of 111) with videos related to

Sort By:
Pageof 12
The Lancet. Haematology|February 22, 2017
Lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplantation: an open label, single-arm, multicentre phase 2 trialAndrés J M Ferreri, Marianna Sassone, Francesco Zaja, et al.
Oncotarget|June 15, 2018
A novel <i>ex vivo</i> high-throughput assay reveals antiproliferative effects of idelalisib and ibrutinib in chronic lymphocytic leukemiaDaniel Primo, Lydia Scarfò, Aliki Xochelli, et al.
Cell Reports|February 16, 2016
Targeting Macrophages Sensitizes Chronic Lymphocytic Leukemia to Apoptosis and Inhibits Disease ProgressionGiovanni Galletti, Cristina Scielzo, Federica Barbaglio, et al.
Blood Advances|May 31, 2022
High surface IgM levels associate with shorter response to ibrutinib and BTK bypass in patients with CLLGiorgia Chiodin, Samantha Drennan, Enrica A Martino, et al.
The Lancet. Oncology|September 13, 2024
Atezolizumab, venetoclax, and obinutuzumab combination in Richter transformation diffuse large B-cell lymphoma (MOLTO): a multicentre, single-arm, phase 2 trialAlessandra Tedeschi, Anna Maria Frustaci, Adalgisa Condoluci, et al.
Hemasphere|March 18, 2025
Loss of CYLD promotes splenic marginal zone lymphomaAthanasios Pseftogas, Jessica Bordini, Silvia Heltai, et al.
Frontiers in Oncology|December 8, 2022
Obinutuzumab plus chlorambucil versus ibrutinib in previously untreated chronic lymphocytic leukemia patients without TP53 disruptions: A real-life CLL campus studyAndrea Visentin, Francesca Romana Mauro, Gioachino Catania, et al.
Leukemia & Lymphoma|March 8, 2022
Lenalidomide enhances CD23.CAR T cell therapy in chronic lymphocytic leukemiaSarah Tettamanti, Maria Caterina Rotiroti, Greta Maria Paola Giordano Attianese, et al.
ESMO Open|January 21, 2020
EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for haematological malignanciesBarbara Kiesewetter, Nathan I Cherny, Nicolas Boissel, et al.
Leukemia|April 4, 2024
IκBε deficiency accelerates disease development in chronic lymphocytic leukemiaJessica Bordini, Chiara Lenzi, Michela Frenquelli, et al.
Pageof 12